Vivos management to present at 11:45 am Eastern Time on November 17, 2021 HIGHLANDS RANCH Colorado, December 9, 2021 Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, today…

Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening of Live Training Facility, Expansion of Marketing Programs, Additional FDA Approval and Positive Study Results Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH Colorado, November 15, 2021 Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a…

Vivos management to present at 11:45 am Eastern Time on November 17, 2021 HIGHLANDS RANCH Colorado, November 15, 2021 Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA), today announced that Kirk Huntsman, Chief Executive Officer, Brad…

Call Scheduled for Monday, November 15, 2021 at 5:00 pm ET HIGHLANDS RANCH   Colorado, November 9, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring in adults,…

Vivos management to present at 12:15 pm Eastern Time on October 27, 2021 HIGHLANDS RANCH Colorado, October 25, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring in…

HIGHLANDS RANCH Colorado, October 18, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, and Candid Care Co. (“Candid”), a digital platform for oral healthcare, today announced a…

HIGHLANDS RANCH Colorado, October 13, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that results from a peer-reviewed, published study by an independent dentist found a…

If Approved for Clearance, Vivos’ Updated Device Will Treat Mild to Moderate Sleep Apnea and Expand Insurance Reimbursement to include Medicare Coverage HIGHLANDS RANCHColorado, September 29, 2021  Vivos Therapeutics, Inc. (“Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea…

Vivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company’s Technology for Obstructive Sleep Apnea Drs. Clete Kushida of Stanford and Cecilia Wu of University of Alberta to lead a team of prominent, multi-disciplinary medical doctors guiding research and fostering increased physician-dental collaboration in the management of obstructive-sleep apnea HIGHLANDS RANCHColorado, September 23,…

Vivos Therapeutics to Participate at the Benzinga Healthcare Small Cap Conference Vivos management to present at 2:20 pm Eastern Time on September 29, 2021 HIGHLANDS RANCH Colorado, September 22, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering…